Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
|
|
14.
|
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. [electronic resource] by
- Huijberts, Sanne C F A
- van Geel, Robin M J M
- van Brummelen, Emilie M J
- Opdam, Frans L
- Marchetti, Serena
- Steeghs, Neeltje
- Pulleman, Saskia
- Thijssen, Bas
- Rosing, Hilde
- Monkhorst, Kim
- Huitema, Alwin D R
- Beijnen, Jos H
- Bernards, René
- Schellens, Jan H M
Producer: 20201117
In:
Cancer chemotherapy and pharmacology vol. 85
Availability: No items available.
|
|
15.
|
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. [electronic resource] by
- van Geel, Robin M J M
- van Brummelen, Emilie M J
- Eskens, Ferry A L M
- Huijberts, Sanne C F A
- de Vos, Filip Y F L
- Lolkema, Martijn P J K
- Devriese, Lot A
- Opdam, Frans L
- Marchetti, Serena
- Steeghs, Neeltje
- Monkhorst, Kim
- Thijssen, Bas
- Rosing, Hilde
- Huitema, Alwin D R
- Beijnen, Jos H
- Bernards, René
- Schellens, Jan H M
Producer: 20201230
In:
British journal of cancer vol. 122
Availability: No items available.
|